Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

21 results
Display

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder

Shin C, Pae CU, Kwak KP, Jeon SW, Jeong HG, Kim JW, Lee YJ, Patkar AA, Han C

Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study

Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS

Objective: In a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (AOM) has been found to be effective and safe as acute and maintenance treatment options for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Possible Modulatory Role of ARC Gene Variants in Mood Disorders

Crisafulli C, Calabrò M, Mandelli L, Wang SM, Lee SJ, Han C, Patkar A, Masand P, Pae CU, Souery D, Mendlewicz J, Serretti A

Objective: The genetic background of mood disorders is gradually emerging through the use of large multicenter samples but a detailed phenotyping is complementary in elucidating the role of modulating variants. Methods:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders

Calabrò M, Mandelli L, Crisafulli C, Nicola MD, Colombo R, Janiri L, Lee SJ, Jun TY, Wang SM, Masand PS, Patkar AA, Han C, Pae CU, Serretti A

Objective: Genetic variations in the gene encoding zinc finger protein 804A gene (ZNF804A) have been associated with major depression and bipolar disorder. In this work we focused on the potential...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study

Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS

Objective: This study was done for collection of real world data of Aripiprazole Once Monthly (AOM) in patients with schizophrenia. Methods: The observation was up to 12 months from the first...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

Han Cs, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1

Calabrò M, Mandelli L, Crisafulli C, Lee SJ, Jun TY, Wang SM, Patkar AA, Masand PS, Han C, Pae CU, Serretti A

OBJECTIVE: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study

Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU

OBJECTIVE: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. METHODS: Data were collected...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU

The Acknowledgement was published incorrectly.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review

Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU

Randomized trials have shown that selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have better safety profiles than classical tricyclic antidepressants (TCAs). However, an increasing number of studies,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A

OBJECTIVE: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. METHODS: An 8-week, randomized, single-blind clinical trial was conducted to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study

Jeon SW, Han C, Ko YH, Yoon SY, Pae CU, Choi J, Park YC, Kim JW, Yoon HK, Ko SD, Patkar AA, Zimmerman

OBJECTIVE: This study was aimed at evaluating the diagnostic validity of the Korean version of the Clinically Useful Depression Outcome Scale (CUDOS) with varying follow-up in a typical clinical setting...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Vilazodone for the Treatment of Depression: An Update

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU

Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU

We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epistatic Interactions between CREB and CREM Variants in Affective Disorder

Chiesa A, Marsano A, Han C, Lee SJ, Patkar AA, Pae CU, Serretti A

The aim of the present work is to investigate the existence of epistatic interactions possibly influencing psychotropic agents' response between rs6740584 within Cyclic adenosine monophosphate Response Element Binding (CREB) and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder

Porcelli S, Pae CU, Han C, Lee SJ, Patkar AA, Masand PS, Balzarro B, Alberti S, De Ronchi , Serretti A

OBJECTIVE: The present study aimed to explore whether 4 single nucleotide polymorphisms (SNPs) within the AHI1 gene could be associated with major depressive disorder (MD) and bipolar disorder (BD), and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tools for Quality Evaluation of Clinical Research Reports

Shin C, Han C, Pae CU, Patkar AA

  • KMID: 1966993
  • Korean J Psychopharmacol.
  • 2011 Apr;22(2):67-72.
Quality of medical research reports should be evaluated before they are applied to clinical practice. Since 1990s, several guidelines on research reports were suggested. Most recently published Consolidated Standards of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective

Marks DM, Patkar AA, Masand PS, Pae CU

  • KMID: 2315817
  • Psychiatry Investig.
  • 2009 Jun;6(2):55-58.
Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Triple Reuptake Inhibitors: A Premise and Promise

Marks DM, Pae CU, Patkar AA

  • KMID: 2315789
  • Psychiatry Investig.
  • 2008 Sep;5(3):142-147.
On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr